Pilot randomized phase II study of celecoxib in oral premalignant lesions
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Celecoxib at 100 or 200 mg twice daily was ineffective in controlling OPLs in this randomized controlled trial. This result and cardiovascular toxicity results of other (large scale) randomized controlled trials of selective COX-2 inhibitors have discouraged the continued investigation of these agents in oral cancer chemoprevention. Better methods for identifying high-risk patients and more active interventions are needed for future oral cancer chemoprevention trials.